GAITHERSBURG, Md., March 5,
2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq:
YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, today announced changes to its
board of directors (the "Board") and key strategic appointments
within its wholly-owned subsidiaries in China.
Each of Mr. Bo Tan and Mr.
Shaojing Tong has resigned as a
director of the Company for personal reasons, effective from
February 29, 2024. Their resignation
did not result from any disagreement with the Company on any matter
relating to the Company's operations, policies, or practice.
Following such resignation, the Board currently consists of ten
directors, including: (1) Dr. Ajit
Shetty (Chairperson of the Board and the Nominating and
Corporate Governance Committee), (2) Dr. Hui Shao (David), (3) Ms. Chunyuan Wu (Brenda), (4) Dr. Viren Mehta (Chairperson of Compensation
Committee), (5) Ms. Rachel Yu
(Chairperson of Audit Committee), (6) Dr. Jin Wang, (7) Mr. Haitao
Zhao, (8) Mr. Henry Chen, (9)
Mr. Pierson Yue Pan, and (10) Mr.
Yuntao Cui.
Furthermore, YishengBio (Hong
Kong) Holdings Limited ("YishengBio Hong Kong"), a
wholly-owned subsidiary of the Company, has designated Ms.
Chunyuan (Brenda) Wu, the Company's
CFO and a Board director, as the new legal representative and
executive director of Beijing Yisheng Biotechnology Co., Ltd., one
of YishengBio Hong Kong's wholly-owned subsidiaries in China, for a term of 3 years, effective from
March 2, 2024. Additionally,
YishengBio Hong Kong has appointed Mr. Gang Li, the Company's Head
of Marketing and Sales, as the new legal representative and
chairman of the board of directors of Liaoning Beijing Yisheng
Biopharmaceutical Co., Ltd., another wholly-owned subsidiary in
China, for a term of 3 years,
effective from March 2, 2024.
Following such new appointments, the senior officers of YS
Biopharma includes (1) Dr. Hui Shao
(David, President & CEO, Director), (2) Ms. Chunyuan Wu (Brenda, CFO), (3) Dr. Zenaida Mojares (Chief Medical Officer), (4) Mr.
Gang Li (Head of Marketing and Sales), and (5) Dr. Yuan Liu (Head
of Vaccine Research).
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and commercializing new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary
PIKA® immunomodulating technology platform and a series
of preventive and therapeutic biologics with a potential for
improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles
vaccines. YS Biopharma operates in China, the United
States, Singapore and
the Philippines, and is led by a
management team that combines rich local expertise and global
experience in the bio-pharmaceutical industry. For more
information, please visit investor.ysbiopharm.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-board-changes-and-strategic-leadership-appointments-in-chinese-subsidiaries-302079837.html
SOURCE YS Biopharma Co., Ltd.
